CheckMate914
Descrição
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
日本がん対策図鑑 【腎細胞がん：術後治療（DFS）】「オプジーボ＋ヤーボイ」vs「経過観察」
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
CheckMate-914 trial's disappointing results cast doubt on BMS's plans to advance PD-1 inhibitors
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States - Clinical Genitourinary Cancer
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma
ScienceLink on X: #Nivolumab #Ipilimumab #CheckMate914 #ScienceLink CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914 / X
Checkpoint inhibitor immunotherapy in kidney cancer
Adjuvant Nivolumab/Ipilimumab Fails to Meet DFS End Point in Localized RCC
CheckMate914
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status
de
por adulto (o preço varia de acordo com o tamanho do grupo)
